{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:56:20Z","timestamp":1786787780508,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T00:00:00Z","timestamp":1423526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40265-015-0357-2","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T05:40:50Z","timestamp":1423460450000},"page":"419-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Naloxegol: A Review of Its Use in Patients with Opioid-Induced Constipation"],"prefix":"10.1007","volume":"75","author":[{"given":"Karly P.","family":"Garnock-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"issue":"14","key":"357_CR1","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2165\/11634970-000000000-00000","volume":"72","author":"C Brock","year":"2012","unstructured":"Brock C, Olesen S, Olesen A, et al. Opioid-Induced Bowel Dysfunction. Drugs. 2012;72(14):1847\u201365.","journal-title":"Drugs."},{"key":"357_CR2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/nmo.12417","volume":"26","author":"M Camilleri","year":"2014","unstructured":"Camilleri M, Drossman DA, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26:1386\u201395.","journal-title":"Neurogastroenterol Motil."},{"key":"357_CR3","unstructured":"AstraZeneca. Movantik\u2122 (naloxegol tablets): US prescribing information. 2014. http:\/\/www.astrazeneca-us.com\/cgi-bin\/az_pi.cgi?product=movantik&country=us&popup=no . Accessed 23 Jan 2015."},{"key":"357_CR4","unstructured":"European Medicines Agency. Moventig\u00ae (naloxegol oxalate tablets): EU summary of product characterisitics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002810\/WC500179075.pdf . Accessed 23 Jan 2015."},{"key":"357_CR5","unstructured":"AstraZeneca. Naloxegol (NDA 204-760) Briefing Document for the Anesthetic and Analgesic Drug Products Advisory Committee. 2014. http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/anestheticandanalgesicdrugproductsadvisorycommittee\/ucm400209.pdf . Accessed 27 Nov 2014."},{"key":"357_CR6","unstructured":"Eldon M, Song D, Neumann TA, et al. NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone: demonstration of selective peripheral opioid antagonism after oral administration in preclinical models [abstract no. 28 plus poster]. In: 18th annual clinical meeting of the American Academy of Pain Management. 2007."},{"key":"357_CR7","unstructured":"Neumann TA, et al. Evaluation of PEG-Naloxol (NKTR-118) as an oral peripheral Opioid Antagonist in healthy male subjects: a double-blind, placebo-controlled, dose escalation crossover study [abstract no. II-36]. In: 36th annual meeting of the American College of Clinical Pharmacology. 2007."},{"issue":"9","key":"357_CR8","first-page":"1123","volume":"49","author":"A Odinecs","year":"2009","unstructured":"Odinecs A, Gadiraju R, Sisco J, et al. Comparative bioavailability of NKTR-118 tablets and solution: a case of bioequivalence between dosage forms for a rapidly absorbed drug [abstract no. 140]. J Clin Pharmacol. 2009;49(9):1123.","journal-title":"J Clin Pharmacol."},{"issue":"12","key":"357_CR9","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2013.09.019","volume":"35","author":"C Gottfridsson","year":"2013","unstructured":"Gottfridsson C, Carlson G, Lappalainen J, et al. Evaluation of the effect of naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT\/QTc study in healthy volunteers. Clin Ther. 2013;35(12):1876\u201383.","journal-title":"Clin Ther."},{"key":"357_CR10","unstructured":"Bui KH, Hutchison M, Brunnstrom A, et al. Absorption, Metabolism and Excretion of [14C]-Naloxegol in Human Subjects [abstract no. R6319 plus poster]. In: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. 2013."},{"issue":"4 Suppl 2","key":"357_CR11","doi-asserted-by":"crossref","first-page":"P28","DOI":"10.1016\/j.jpain.2008.01.131","volume":"9","author":"D Sahner","year":"2008","unstructured":"Sahner D, van Paaschen H, et al. Results from a phase I, double-blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118 [abstract no. 210 plus poster]. J Pain. 2008;9(4 Suppl 2):P28.","journal-title":"J Pain"},{"key":"357_CR12","doi-asserted-by":"crossref","unstructured":"Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014. doi: 10.1002\/jcph.348 .","DOI":"10.1002\/jcph.348"},{"key":"357_CR13","author":"K Bui","year":"2014","unstructured":"Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;. doi: 10.1002\/jcph.349 .","journal-title":"J Clin Pharmacol."},{"issue":"Suppl. 1","key":"357_CR14","first-page":"S53","volume":"95","author":"K Bui","year":"2014","unstructured":"Bui K, Zhou D, Sostek M, et al. Effects of CYP3A modulators on the PK of naloxegol [abstract no. PI-108]. Clin Pharmacol Ther. 2014;95(Suppl. 1):S53.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl. 1","key":"357_CR15","first-page":"8","volume":"2","author":"KH Bui","year":"2013","unstructured":"Bui KH, She F, Zhou D, et al. Evaluation of the effect of quinidine, a strong Pgp inhibitor, on the pharmacokinetics and CNS distribution of naloxegol [abstract no. 1710175]. Clin Pharmacol Drug Dev. 2013;2(Suppl. 1):8\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"357_CR16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.pain.2013.04.024","volume":"154","author":"L Webster","year":"2013","unstructured":"Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542\u201350.","journal-title":"Pain."},{"issue":"25","key":"357_CR17","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","volume":"370","author":"WD Chey","year":"2014","unstructured":"Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387\u201396.","journal-title":"N Engl J Med."},{"issue":"Suppl. 1","key":"357_CR18","first-page":"S570","volume":"108","author":"W Chey","year":"2013","unstructured":"Chey W, Tack J, Webster L, et al. Efficacy of naloxegol in a subpopulation of patients with opioid-induced constipation and an inadequate baseline response to laxatives: results from two, prospective, randomized controlled trials [abstract no. 1884]. Am J Gastroenterol. 2013;108(Suppl. 1):S570.","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"357_CR19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/apt.12899","volume":"40","author":"L Webster","year":"2014","unstructured":"Webster L, Chey WD, Tack J, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771\u20139.","journal-title":"Aliment Pharmacol Ther."},{"key":"357_CR20","first-page":"S259","volume":"21","author":"JH Roenn Von","year":"2013","unstructured":"Von Roenn JH, Tack J, Barker PN, et al. Challenges in patient recruitment during KODIAC-06, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial of naloxegol in patients with neoplasia and opioid-induced constipation (OIC). Support Care Cancer. 2013;21:S259.","journal-title":"Support Care Cancer."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0357-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0357-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0357-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:41Z","timestamp":1559490101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0357-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0357-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,10]]}}}